{"disease":{"id":"hypogammaglobulinemia","name":"hypogammaglobulinemia","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"mavorixafor","indication_name":"hypogammaglobulinemia","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xolremdi","generic_name":"MAVORIXAFOR","company_name":"X4 Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"CXC Chemokine Receptor 4 Antagonist [EPC]","quality_score":54,"revenue":null,"mechanism":"Xolremdi blocks the CXC Chemokine Receptor 4 to treat WHIM syndrome."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04447937","title":"Immunodeficiency in MS","phase":"","overall_status":"UNKNOWN","enrollment_count":1500,"lead_sponsor_name":"Advanced Neurosciences Institute","has_results":false},{"nct_id":"NCT04502030","title":"Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia (\"PRO-SID\" Study)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":247,"lead_sponsor_name":"Octapharma","has_results":false},{"nct_id":"NCT05357781","title":"Immunoglobulin Deficiency a Treatable Cause of Fatigue in Patients With Multiple Sclerosis (MS)?","phase":"","overall_status":"RECRUITING","enrollment_count":106,"lead_sponsor_name":"Insel Gruppe AG, University Hospital Bern","has_results":false},{"nct_id":"NCT06976476","title":"Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05321407","title":"COVID-19 Vaccine Responses in PIDD Subjects","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT01581593","title":"Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Kedrion S.p.A.","has_results":true},{"nct_id":"NCT01002755","title":"Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT06989541","title":"Immunoglobulin for Hypogammaglobulinemia Due to Chimeric Antigen Receptor T Cell Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"University of Alberta","has_results":false},{"nct_id":"NCT00161993","title":"Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Baxalta now part of Shire","has_results":false},{"nct_id":"NCT02231879","title":"Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT03401268","title":"Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT02508584","title":"Personalized Immunotherapeutic for Antibiotic-resistant Infection","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":1,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false}],"total":12},"guidelines":[],"source":"Drug Landscape verified database"}